BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, Alqarni M, Batiha GE, Obaidullah AJ, Shahien MA, El-Ahwany E, Amin NA, Etman MA, Kaddah MMY, Abd El-Fattah EE. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed Pharmacother 2022;145:112455. [PMID: 34844106 DOI: 10.1016/j.biopha.2021.112455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Nalla LV, Khairnar A. Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur J Pharmacol 2023;:175565. [PMID: 36739077 DOI: 10.1016/j.ejphar.2023.175565] [Reference Citation Analysis]
2 Saber S, El-fattah EEA, Abdelhamid AM, Mourad AA, Hamouda MAM, Elrabat A, Zakaria S, Haleem AA, Mohamed SZ, Elgharabawy RM, Morsy NE, El Adle Khalaf N, Mohammed OA, El-bahouty WB, Mostafa SA, Abdelhady R, Galal O, Elsaid ZH, Yahya G, Shata A, Youssef ME. Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling. Biomedicine & Pharmacotherapy 2023;158:114196. [DOI: 10.1016/j.biopha.2022.114196] [Reference Citation Analysis]
3 Abd El-Fattah EE. Tumor lysis syndrome promotes cancer chemoresistance and relapse through AMPK inhibition. Int Immunopharmacol 2023;114:109568. [PMID: 36527883 DOI: 10.1016/j.intimp.2022.109568] [Reference Citation Analysis]
4 Abd El-fattah EE, Selim HM. Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. International Immunopharmacology 2022;113:109475. [DOI: 10.1016/j.intimp.2022.109475] [Reference Citation Analysis]
5 Abd El-fattah EE, Zakaria AY. Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management. J Transl Med 2022;20:544. [DOI: 10.1186/s12967-022-03759-z] [Reference Citation Analysis]
6 Al-kuraishy HM, Al-gareeb AI, Elekhnawy E, Batiha GE. Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail. Egypt J Med Hum Genet 2022;23. [DOI: 10.1186/s43042-022-00354-1] [Reference Citation Analysis]
7 Nasr M, Cavalu S, Saber S, Youssef ME, Abdelhamid AM, Elagamy HI, Kamal I, Gaafar AGA, El-ahwany E, Amin NA, Girgis S, El-sandarosy R, Mahmoud F, Rizk H, Mansour M, Hasaballah A, El-rafi AA, El-azez RA, Essam M, Mohamed D, Essam N, Mohammed OA. Canagliflozin-loaded chitosan-hyaluronic acid microspheres modulate AMPK/NF-κB/NLRP3 axis: A new paradigm in the rectal therapy of ulcerative colitis. Biomedicine & Pharmacotherapy 2022;153:113409. [DOI: 10.1016/j.biopha.2022.113409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Abd El-fattah EE, Zakaria AY. Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach. International Immunopharmacology 2022;109:108889. [DOI: 10.1016/j.intimp.2022.108889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Abdelhamid AM, Youssef ME, Cavalu S, Mostafa-Hedeab G, Youssef A, Elazab ST, Ibrahim S, Allam S, Elgharabawy RM, El-Ahwany E, Amin NA, Shata A, Mohammed OA, Ibrahim Abdeldaiem MS, Alhowail A, El-Saber Batiha G, El-Mahmoudy EA, Attia M, Allam A, Zaater MY, Osman MM, Nader M, Taha A, Makarem NA, Saber S. Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. Front Pharmacol 2022;13:887233. [PMID: 35754464 DOI: 10.3389/fphar.2022.887233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Filisola-villaseñor JG, Aranda-barradas ME, Miranda-castro SP, Mendieta-wejebe JE, Valdez Guerrero AS, Guillen Castro SA, Martínez Castillo M, Tamay-cach F, Álvarez-almazán S. Impact of Molecular Symmetry/Asymmetry on Insulin-Sensitizing Treatments for Type 2 Diabetes. Symmetry 2022;14:1240. [DOI: 10.3390/sym14061240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Saber S, Nasr M, Kaddah MMY, Mostafa-Hedeab G, Cavalu S, Mourad AAE, Gaafar AGA, Zaghlool SS, Saleh S, Hafez MM, Girgis S, Elgharabawy RM, Nader K, Alsharidah M, Batiha GE, El-Ahwany E, Amin NA, Elagamy HI, Shata A, Nader R, Khodir AE. Nifuroxazide-loaded cubosomes exhibit an advancement in pulmonary delivery and attenuate bleomycin-induced lung fibrosis by regulating the STAT3 and NF-κB signaling: A new challenge for unmet therapeutic needs. Biomed Pharmacother 2022;148:112731. [PMID: 35220029 DOI: 10.1016/j.biopha.2022.112731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]